The analyze confirmed no unusual threats, which indicated that it may be safely administered in a scientific research context. Afterwards, Dr. Charles Grob requested permission to more review the substance with cancer individuals, but was denied with the FDA 2 times.Although copyright is assessed as being a Agenda I compound in the United States �